Clinical Effect of Yinma Zhisou Decoction Combined with Western Medicine in the Treatment of Acute COPD(Stagnation of PhlegmDampness in Lung)

[Objectives]To explore the effectiveness and safety of Yinma Zhisou Decoction in the treatment of AECOPD with phlegm-heat obstructing lung syndrome,and observe the symptoms of Yinma Zhisou decoction in the treatment of AECOPD patients with phlegm-heat stagnation lung syndrome improvement,inflammatory indicators,lung function,blood gas analysis,etc.[Methods]A total of 92 cases who met the inclusion criteria and exclusion criteria were included in the study according to 1∶1 were randomly divided into treatment group and control group,control group with conventional Western medicine treatment,the treatment group on the basis of control group with Yinma Zhisou decoction treatment,a course of 10 d.The changes in TCM syndrome score,arterial blood gas analysis,pulmonary function,serum inflammatory indicator,mMRC score,and the CAT scores between the two groups after treatment were observed.All collected data were statistically analyzed with SPSS 26.0.[Results](i)Comparison of the curative effect between the two groups.After treatment,the total effective rate of the treatment group was 93.5%,which was higher than that of the control group(76.1%,P<0.05).The curative effect of the treatment group was better than that of the control group(P<0.05).(ii)Comparison of single TCM symptom scores.After treatment,the single TCM symptom scores of the two groups were lower than before(P<0.05),but the improvement of wheezing,cough,phlegm and chest pain in the treatment group was better than that in the control group(P<0.05).There was no significant difference in the improvement of wheezing sound(P>0.05),but there was a trend of difference.(iii)Comparison of mMRC score and CAT score between the two groups.After treatment,the mMRC score and CAT score of the two groups were significantly improved(P<0.05),and the difference was statistically significant.(iv)Comparison of blood gas analysis indicators between the two groups.Intra-group comparison after treatment:PaOof the control group and the treatment group after treatment was significantly improved compared with that before treatment(P<0.05),and the difference was statistically significant.Comparison between the two groups after treatment:PaOand PaCOof the two groups after treatment(P>0.05),and the difference was not statistically significant.It indicated that Yinma Zhisou decoction had more advantages in improving hypoxia.(v)Comparison of pulmonary function between the two groups.After treatment,the FEV1/FVC of the treatment group and the control group was significantly different(P<0.05),and there was a statistical difference(P<0.05).(vi)Comparison of inflammatory indicators between the two groups.Intra-group comparison after treatment:the inflammatory indicators WBC,CRP and PCT in the control group and the treatment group were significantly lower than before treatment(P<0.05),and the differences were statistically significant.It indicated that Yinma Zhisou decoction could effectively control inflammation and reduce inflammation reaction.[Conclusions]Compared with the control group,Yinma Zhisou decoction has obvious advantages in improving cough,expectoration and wheezing,and can significantly improve the total effective rate.Compared with Western medicine alone,Yinma Zhisou decoction can significantly improve patients’hypoxia,reduce mMRC and CAT scores,improve body activity tolerance,improve airway symptoms,and significantly reduce WBC,CRP,PCT and other serum inflammatory indicators.It can be seen that Yinma Zhisou decoction combined with Western medicine treatment is obviously better than simple Western medicine treatment,the curative effect is better,and the safety is better,and there are no serious adverse reactions in the course of the trial.

Discussion on the Prevention and Treatment of COVID-19 Causing Lung Disease and Heart Damage Based on Lei Zhongyi's Theory of Intermingled Phlegm,Blood Stasis and Toxin

Novel coronavirus infection not only damages lung function,but also causes myocardial injury,elevated myocardial enzymes and heart failure,especially for patients with basic heart diseases who develop COVID-19,the first consideration should be the protection of cardiac function.Based on the theory of intermingled phlegm,blood stasis and toxin of heart disease put forward by Master Lei Zhongyi,the dialectical treatment thinking of COVID-19 patients from the concept of damage of phlegm,blood stasis and toxin to the heart were discussed.During the diagnosis,critical stage and recovery period of COVID-19,expectorant and blood-activating agents,heat and detoxification agents can be added to promote lung and asthma,free Bizheng and remove blood stasis,calm the heart and calm the mind,and promote the recovery of cardiopulmonary functions.

Clinical Efficacy of Modified Erchen Decoction on Cervical Spondylotic Vertebral Arteriopathy with Stagnation and Blockade of Phlegm-dampness Syndrome and Effects on Cerebral Blood Flow Parameters

OBJECTIVE: To observe the effect of Modified Erchen Decoction on cervical spondylotic vertebral arteriopathy with stagnation and blockade of phlegm-dampness syndrome and effects on cerebral blood flow parameters. METHODS: A total of 80 cervical spondylotic vertebral arteriopathy(CSA) patients with stagnation and blockade of phlegmdampness syndrome admitted to our hospital from October 2016 to April 2017 were selected and randomly divided into observation group and control group, with 40 cases in each group. The observation group was treated with Modified Erchen Decoction and the control group was given conventional treatment with Western medicine. After 4 weeks of treatment, the main clinical symptoms and signs(vertigo, neck and shoulder pain, headache, psychological and social adjustment, daily life and work) and cerebral blood flow parameters [the peak values of intracranial vertebral-basal artery diastolic blood flow velocity(Vd) and systolic blood flow velocity(Vp)] were compared between the 2 groups. The total clinical effective rate and adverse reactions during treatment were also compared. RESULTS: After treatment, the total effective rate of the observation group was 90.0%, which was significantly higher than that of the control group(77.5%). The difference between the two groups was statistically significant(P < 0.05). After treatment, The scores of vertigo, neck and shoulder pain, headache, psychology and society adaptation, daily life and work were significantly increased(P < 0.05), and the above scores of the observation group were increased more obviously. The difference between the groups was statistically significant(P < 0.05). After treatment, the levels of Vd and Vp were significantly increased(P < 0.05), and the increase of the above indexes was more obvious in the observation group. The difference between the 2 groups was statistically significant(P < 0.05). There were no significant abnormalities in blood routine, urine routine, liver function and renal function. There was no significant difference in the incidence of adverse reactions between the 2 groups.(P > 0.05). CONCLUSION: The treatment of vertebral artery type cervical spondylopathy with stagnation and blockade of phlegm-dampness syndrome by Modified Erchen Decoction can effectively relieve the main clinical symptoms and signs, improve cerebral blood flow parameters, and improve the peak values of vertebral-basal artery diastolic blood flow velocity(Vd) and systolic blood flow velocity(Vp), which is safe and effective, and helps to promote the recovery of cervical function.

Clinical study on Chuanxiong Hualiu Mixture in the treatment of blood stasis and phlegm stagnation type of ovarian cyst

Objective:To observe the clinical efficacy of Chuanxiong Hualiu Mixture in the treatment of blood stasis and phlegm stagnation type of ovarian cyst and the effects on physical and chemical indicators.Methods: A total of 80 patients with blood stasis and phlegm stagnation type of ovarian cyst were randomly divided into two groups, research group (n=40) took Chuanxiong Hualiu Mixture, control group (n=40) took Guizhi Fuling Capsule, 3 months was a course of treatment, and the curative effect was compared between two groups.Results:(1) The overall response rate of Chuanxiong Hualiu mixture group after 3 months of treatment was 82.5%, that of Guizhi Fuling Capsule group was 62.5%, the overall response rate of Chuanxiong Hualiu mixture group was higher than that of control group, and the difference was statistically significant;(2) before and after treatment, sex hormone and hemorheology index E2 of both groups decreased significantly, whole blood viscosity, whole blood reduced viscosity and plasma viscosity decreased significantly, the results were statistically significant, but there was no difference between two groups;(3) rank sum test of TCM symptom efficacy between two groups before and after treatment showed that the overall response rate of Chuanxiong Hualiu mixture group was 95%, the overall response rate of Guizhi Fuling Capsule group was 85%, the overall response rate of research group was better than that of control group, and the difference was statistically significant.Conclusion:Chuanxiong Hualiu mixture has good curative effect for the treatment of ovarian cyst, it can effectively improve the patients' blood stasis and phlegm stagnation constitution, and its mechanism of action is associated with lowering estrogen levels and improving hemorrheology.

岭南地区亚健康人群睡眠状况与中医体质类型的相关性研究

【目的】探究岭南地区亚健康人群睡眠状况与中医体质类型的相关性。【方法】选取2022年5月~2023年5月于深圳市宝安区中医院治未病中心就诊的688例在深圳市居住5年以上,无严重心血管疾病,经亚健康人群评定量表评定为亚健康的人群为研究对象,采用匹兹堡睡眠质量指数(PSQI)量表、中医体质评定量表对其进行问卷调查,并将其睡眠状况与中医体质类型进行多元线性回归分析。【结果】(1)调查问卷发放回收情况:共发放688份问卷,其中,失访19份,回收669份,剔除无效问卷29份,最终共纳入有效问卷640份。(2)不同睡眠状况人群的PSQI量表评分情况:根据PSQI量表得分情况将人群分为睡眠优组(PSQI总分<8分)350例和睡眠差组(PSQI总分≥8分)290例,组间比较,睡眠优组的入睡时间、睡眠时间、睡眠障碍得分以及总分均明显低于睡眠差组(P<0.05或P<0.01)。(3)不同睡眠状况人群的中医体质类别分布情况:睡眠优者多表现为平和质(86.86%),睡眠差者多表现为偏颇体质(79.64%)。睡眠差人群中,偏颇体质排前3位的分别是湿热质(15.52%)、痰湿质(13.79%)以及气郁质(13.10%)。(4)多元线性回归分析结果显示,入睡时间与痰湿质、气郁质呈正相关(P<0.01),与平和质呈负相关(P<0.05);睡眠效率与湿热质、特禀质呈正相关(P<0.05或P<0.01),与平和质呈负相关(P<0.05);睡眠障碍与气郁质、阴虚质呈正相关(P<0.01);催眠药物与阴虚质呈正相关(P<0.01);日间功能障碍与痰湿质呈正相关(P<0.05)。【结论】岭南地区亚健康人群睡眠状况与其中医体质类型具有一定相关性,湿热质、痰湿质、气郁质、阴虚质、平和质、特禀质是影响睡眠状况主要的6种中医体质类别;结合中医体质辨识指导亚健康人群通过改善其体质从而达到未病先防的目的是很有意义的。

宣肺降浊清肠汤治疗稳定期支气管扩张症疗效及对肠道微生态的影响

目的观察宣肺降浊清肠汤治疗稳定期支气管扩张患者的效果及对肠道微生态的影响。方法选取2022年1月—2023年1月广州医科大学附属第一医院收治的稳定期支气管扩张症痰湿蕴肺型患者90例为观察对象,随机分为西药组、中药组、中西医结合组,每组各30例;同时于广州医科大学附属第一医院体检中心随机选取30例健康者作为空白组,用于肠道菌群检测的对照。西药组给予氨溴索口服,中药组给予宣肺降浊清肠汤颗粒剂口服,中西医结合组给予宣肺降浊清肠汤联合氨溴索口服。连续治疗6个月后评估3组临床疗效,比较3组治疗前后肺功能指标[第一秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、呼气峰值流速(PEF)]、支气管扩张严重程度指数(BSI)评分、24 h痰量、急性加重次数、咳嗽-咳痰评估问卷(CASA-Q)评分、圣乔治呼吸问卷(SGRQ)评分及粪便标本中直肠真杆菌、多形拟杆菌表达量(采用PCR扩增法测定)。结果治疗结束后,中西医结合组临床总有效率明显高于中药组、西药组[93.3%(28/30)比63.3%(18/30)、76.7%(23/30),P均<0.05]。与治疗前比较,治疗后3组FEV_(1)、FVC、PEF均明显提高,BSI评分、SGRQ评分均明显降低,24 h痰量、急性加重次数均明显减少,CASA-Q评分均明显升高,且中西医结合组各指标改善情况均明显优于中药组及西药组,西药组各指标改善情况均明显优于中药组,差异均有统计学意义(P均<0.05)。治疗后中西医结合组和中药组粪便中直肠真杆菌、多形拟杆菌表达量均较治疗前明显改善(P均<0.05),西药组粪便直肠真杆菌、多形拟杆菌表达量均无明显变化(P均>0.05);治疗后中药组和中西医结合组直肠真杆菌表达量均明显低于西药组(P均<0.05),多形拟杆菌表达量均明显高于西药组(P均<0.05),中药组和中西医结合组直肠真杆菌、多形拟杆菌表达量比较差异均无统计学意义(P均>0.05)。结论宣肺降浊清肠汤联合氨溴索治疗稳定期支气管扩张症痰湿蕴肺型患者效果优于二者单独应用,可有效缓解患者病情,改善肺功能和生活质量,机制可能与宣肺降浊清肠汤可调节肠道菌群微生态相关。

苏葶止喘汤联合西医治疗小儿支气管哮喘急性发作期(痰热阻肺证)38例

目的探讨苏葶止喘汤联合西医治疗小儿支气管哮喘急性发作期(痰热阻肺证)临床疗效。方法收集2020年2月至2022年3月河北省沧州中西医结合医院就诊的急性发作期的支气管哮喘病儿78例,根据随机数字表法分为对照组与治疗组各39例,对照组病儿给予硫酸沙丁胺醇、异丙托溴铵、布地奈德雾化吸入等西医治疗,治疗组在对照组基础上给予苏葶止喘汤治疗,观察两组治疗前后的临床疗效,症状缓解时间(咳痰消失时间、哮鸣音消失时间、咳嗽消失时间、喘息消失时间),肺功能指标[用力肺活量(FVC)、第1秒用力呼吸容积(FEV_(1))、第1秒用力呼气量占所有呼气量的比例(FEV_(1)/FVC)、最大呼气流量(PEF)、呼气中断流速(PEF25%)、呼吸中期瞬间流速(PEF50%)、呼吸后期瞬间流速(PEF75%)],血清炎症因子指标[C反应蛋白(CRP)、白细胞介素-22(IL-22)、白细胞介素-4(IL-4)],Toll样受体2(TLR2)、Toll样受体4(TLR4)表达水平。结果治疗后治疗组总有效率94.74%显著高于对照组71.05%(P<0.05);治疗组症状缓解时间快于对照组(P<0.05);治疗后两组FVC、FEV_(1)、FEV_(1)/FVC、PEF、PEF25%、PEF50%、PEF75%值均较治疗前升高且治疗组高于对照组(P<0.05);治疗后两组血清CRP、IL-22、IL-4、TLR2、TLR4水平均较治疗前降低,且治疗组CRP[(10.23±3.26)mg/L比(15.25±5.37)mg/L]、IL-22[(37.13±9.84)ng/L比(45.46±11.08)ng/L]、IL-4[(48.15±12.28)ng/L比(56.07±14.36)ng/L]、TLR2[(16.78±1.91)ng/L比(21.15±2.08)ng/L]、TLR4[(18.05±2.53)ng/L比(22.44±3.27)ng/L]低于对照组(P<0.05)。结论苏葶止喘汤联合西医治疗小儿支气管哮喘急性发作期临床疗效显著。

痰热清注射液联合清燥救肺汤立体时相给药治疗放射性肺炎的临床研究

目的:观察痰热清注射液联合清燥救肺汤加减立体时相给药对放射性肺炎(RP)的治疗效果。方法:选择接受胸部三维适形放射治疗,同时中医辨证为痰热阻肺型的肺癌患者100例作为研究对象,随机分为对照组和观察组,每组50例。对照组患者采用单纯放疗,观察组在放疗基础上,给予痰热清静脉注射联合清燥救肺汤加减立体时相给药,于治疗结束后评估2组患者临床疗效及RP发生率,观察2组放疗前、中、后中医证候评分及血清肿瘤坏死因子-α(TNF-α)、转化生长因子-β1(TGF-β1)、白细胞介素-6(IL-6)的水平变化,观察患者放疗前后肺功能指标卡诺夫斯凯计分(KPS)评分的变化。结果:观察组RP发生率较对照组明显降低,临床总有效率明显优于对照组(P<0.05);2组中医证候评分及血清TNF-α、TGF-β1、IL-6水平于放疗后不同时期均明显降低(P<0.05),与对照组比较,观察组放疗后2个月、4个月及放疗结束时中医证候评分及血清TNF-α、TGF-β1、IL-6水平明显降低(P<0.05);观察组肺活量(VC)、用力肺活量(FVC)、第一秒用力呼气量(FEV1)、FEV1/FVC肺功能指标及KPS评分较对照组显著提高(P<0.05)。结论:痰热清注射液联合清燥救肺汤立体时相给药可有效减轻放射治疗所致的放射性肺炎,通过降低血清炎症介质水平,改善肺功能起到减毒增效作用,对提升患者生命质量,提高放疗安全性和有效性具有积极意义。

清咳平喘颗粒对COPD急性加重期的临床疗效

目的探讨清咳平喘颗粒对慢性阻塞性肺疾病急性加重期(AECOPD)患者临床疗效的影响。方法选取80例呼吸科住院治疗的AECOPD患者,其中常规组和联合组各40例,分别于治疗前、治疗第2周末、治疗1个月后观察2组患者自我评估测试(CAT)评分、疗效指数、白细胞介素(IL)-6水平、C-反应蛋白(CRP)水平、第1秒用力呼气容积(FEV1)/用力肺活量(FVC)、FEV1占预计值百分比(FEV1%pred)的差异。结果联合组总有效率高于常规组(92.5%vs.75.0%,P<0.05)。治疗第2周末,2组FEV1%pred、FEV1/FVC、IL-6水平、CRP水平与治疗前比较均有所改善,且联合组改善程度优于常规组(P<0.05),2组患者呼吸衰竭比例均较治疗前明显好转;随访1个月,联合组CAT评分回弹率低于常规组(P<0.05);2组不良反应发生率差异无统计学意义(12.5%vs.2.5%,P>0.05)。结论清咳平喘颗粒能有效改善AECOPD患者的临床症状及肺功能,提高生活质量。

自拟疏肝理气解郁汤对甲状腺癌术后患者的疗效观察

目的 探讨自拟疏肝理气解郁汤对甲状腺癌术后患者的疗效。方法 选取甲状腺癌术后患者85例,中医辨证为气郁痰阻证,随机数字表法分为研究组43例,对照组42例。对照组予以常规治疗(口服左甲状腺素钠片,并进行心理及健康行为指导),研究组在对照组基础上予以自拟疏肝理气解郁汤治疗,2组均治疗3个月。统计2组中医证候疗效,比较治疗前后中医证候积分、负性情绪[21项抑郁-焦虑-压力量表(DASS-21)评分]、免疫功能(CD4^(+)、CD8^(+)、CD3^(+)水平变化)。结果 研究期间研究组依从性差剔除1例,纳入42例;对照组自行退出1例,纳入41例。治疗后研究组主症、次症及舌脉积分低于对照组(P<0.05);治疗后研究组中医证候疗效总有效率(90.48%)高于对照组(73.17%)(P<0.05);治疗后研究组DASS-21评分低于对照组(P<0.05);治疗后研究组CD4^(+)、CD3^(+)水平高于对照组,CD8^(+)水平低于对照组(P<0.05)。结论 自拟疏肝理气解郁汤治疗甲状腺癌术后患者,可明显缓解患者临床症状,减轻负性情绪,调节免疫功能,提高临床疗效。

肺热咳喘方联合常规疗法治疗社区获得性肺炎痰热壅肺证临床研究

目的:观察肺热咳喘方联合常规疗法治疗社区获得性肺炎痰热壅肺证的疗效。方法:选取123例痰热壅肺证社区获得性肺炎患者,按随机数字表法分为对照组60例及联合组63例。对照组采用常规西药治疗,联合组采用肺热咳喘方联合常规西药治疗,2组均治疗2周。观察2组临床疗效、影像学检查结果、不良反应发生情况及临床症状消退时间,比较2组治疗前后中医证候积分、血清C-反应蛋白(CRP)、降钙素原(PCT)、白细胞计数(WBC)水平的变化。结果:治疗后,2组中医证候积分主症、次症、总分均较治疗前下降(P<0.05),联合组中医证候积分主症、次症、总分均低于对照组(P<0.05)。治疗后,联合组退热、咳嗽消退、咳痰消退及肺部啰音消退时间均短于对照组,差异均有统计学意义(P<0.05)。治疗后,2组CRP、PCT、WBC水平均较治疗前下降(P<0.05),联合组上述3项水平均低于对照组(P<0.05)。治疗后,联合组影像学吸收率为95.24%,对照组为81.67%,2组比较,差异有统计学意义(P<0.05)。联合组临床疗效总有效率为95.24%,对照组为81.67%,2组比较,差异有统计学意义(P<0.05)。联合组不良反应发生率为6.35%,对照组不良反应发生率为8.33%,2组比较,差异无统计学意义(P>0.05)。结论:肺热咳喘方联合现代医学治疗社区获得性肺炎痰热壅肺证能明显缓解症状,降低炎症水平,临床疗效显著,且安全性良好。

王文萍从痰瘀论治肺癌经验

王文萍教授认为,肺癌病机为痰瘀互结,临证以活血化瘀、调畅气机为主,软坚散结、化痰祛瘀为辅,方用血府逐瘀汤合二陈汤化裁治疗肺癌,同时注重对患者进行心理疏导,减轻其精神压力,以达到标本兼治的目的。本文从病因病机、治法治则、遣方用药总结王文萍教授治疗肺癌的临证经验,并附验案一则,以期较为全面地分析王文萍从痰瘀论治肺癌的学术思想。

清金化痰汤加减对痰热郁肺型慢性支气管炎急性发作期的临床治疗效果

目的 探究清金化痰汤加减对痰热郁肺型慢性支气管炎急性发作期患者的应用价值。方法选取2019年1月—2022年10月青岛市黄岛区人民医院收治的80例痰热郁肺型慢性支气管炎急性发作期患者进行研究。依据抽签法分为对照组(40例)与研究组(40例),分别实施常规治疗、常规治疗+清金化痰汤治疗。比较两组炎症因子、治疗效果与中医证候积分等。结果 研究组治疗有效率为97.50%,高于对照组的72.50%,差异有统计学意义(χ^(2)=9.804,P<0.05)。研究组复发率低于对照组,差异有统计学意义(P<0.05)。研究组中医证候积分低于对照组,差异有统计学意义(P<0.05)。研究组炎症因子相关指标较对照组低,差异有统计学意义(P<0.05)。结论 清金化痰汤加减应用于痰热郁肺型慢性支气管炎急性发作期患者时,对炎症因子水平及中医证候的改善有一定促进作用,可提高整体治疗效果。

温胆汤加减治疗痰热郁结型冠心病的临床疗效观察

目的观察温胆汤加减治疗痰热郁结型冠心病的临床疗效及安全性。方法纳入合并焦虑症(痰热郁结型)的冠心病患者60例,随机分为中西医结合组30例,西医组30例。西医组患者给予口服给予西药常规治疗加氟哌噻吨美利曲辛片。中西医结合组患者在西医治疗组基础上,联合温胆汤加减,每日2次口服,每次100 ml。两组疗程均为28 d。比较两组治疗的临床疗效和安全性。结果连续治疗28 d后,中西医结合组治疗的临床总有效率90%,高于西医组的76%;中西医结合组中医证候积分明显高于西医组;中西医结合组西雅图心绞痛量表各项评分改善均优于西医组,以上指标比较差异均具有统计学意义(均P<0.05)。两组均未发现明显不良反应。结论对于痰热郁结型冠心病患者,温胆汤加减治疗联合西医常规治疗,相比单纯西医治疗能进一步改善患者心绞痛发作及精神状态,减少心绞痛发作次数,减轻发作程度,且安全性良好。

加味普济消毒颗粒内服联合消肿散结膏外敷治疗儿童急性扁桃体炎的临床研究

【目的】评价加味普济消毒颗粒(由金银花、连翘、蒲公英、紫花地丁、荆芥、牛蒡子、皂角刺、赤芍、牡丹皮、芦根等组成)内服联合消肿散结膏(由黄芩、黄连、黄柏、皂角刺等组成)外敷治疗儿童急性扁桃体炎(acute tonsillitis in children,ATC)的临床疗效及对免疫功能与相关炎症指标的影响。【方法】将116例ATC肺胃郁热证患儿随机分为对照组和观察组,每组各58例。对照组给予头孢克肟分散片治疗,观察组给予加味普济消毒颗粒内服联合消肿散结膏外敷治疗,疗程为14 d并随访6个月。观察2组患儿治疗前后中医证候积分、外周血中白细胞计数(WBC)、T淋巴细胞亚群CD3^(+)、CD4^(+)、CD8^(+)和CD4^(+)/CD8^(+)水平及血清肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)、白细胞介素6(IL-6)、C反应蛋白(CRP)水平的变化情况,比较2组患儿的临床疗效和各项临床症状消失时间,同时监测2组患儿的不良反应发生情况和扁桃体炎复发情况。【结果】(1)研究期间,对照组有8例患儿脱落,观察组无脱落病例,最终对照组50例、观察组58例患儿完成全部疗程的治疗。(2)治疗14 d后,观察组的总有效率为98.28%(57/58),对照组为90.00%(45/50);组间比较(秩和检验),观察组的临床疗效明显优于对照组(P<0.05)。(3)治疗后,观察组患儿的咽痛消失时间、脓点消失时间、退热时间及扁桃体恢复正常时间均较对照组明显缩短(P<0.05)。(4)治疗后,2组患儿的主症积分、次症积分和中医证候总积分均较治疗前明显降低(P<0.05),且观察组的降低幅度均明显优于对照组(P<0.05)。(5)治疗后,2组患儿的T淋巴细胞亚群CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平均较治疗前明显升高(P<0.05),CD8^(+)水平均较治疗前明显降低(P<0.05),且观察组对T淋巴细胞亚群CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平的升高幅度及对CD8^(+)水平的降低幅度均明显优于对照组(P<0.05)。(6)治疗后,2组患儿的WBC、TNF-α、IL-1β、IL-6及CRP水平均较治疗前明显降低(P<0.05),且观察组的降低幅度均明显优于对照组(P<0.05)。(7)治疗期间,2组患儿均未出现皮肤过敏及恶心、呕吐等胃肠道不良反应情况,具有较高的安全性。(8)随访6个月,观察组患儿的扁桃体炎复发率为5.17%(3/58),明显低于对照组的24.00%(12/50),组间比较,差异有统计学意义(χ2=8.330,P<0.05)。【结论】加味普济消毒颗粒内服联合消肿散结膏外敷治疗ATC肺胃郁热证患儿疗效显著,可明显缩短病程,改善临床症状,有效降低扁桃体炎复发率,其机制可能与增强机体免疫功能、抑制炎症反应有关。

从“金郁泄之”论治溃疡性结肠炎

“金郁泄之”理论出自《黄帝内经》,“金”是肺与肠的基本属性,“郁”指郁滞,壅塞不通的异常状态,故“金郁”可理解为属金脏腑如肺、大肠所发壅滞、阻塞之证。“泄之”是五行属金脏腑郁滞的治疗方法,其具体含义应随“金郁”的病理产物、病位的不同而不同。溃疡性结肠炎多由邪蕴肠腑,气血瘀滞,肠道传导失司,湿、热、瘀于大肠相互搏结成郁,改变肠道属金肃降之性所致,其核心病机为湿热内蕴,气血瘀滞,属于“金郁”的范畴,病位虽在大肠,可波及于肺。故治疗应顺应“泄之”的法则,以祛除肺肠之郁为主,包括清泄与宣泄两种方法,同时补益肺、脾、肾三脏之气,以恢复肺肠之功能,达到扶正祛邪,标本兼顾的目的,促进溃疡性结肠炎的愈合。

化痰通络颗粒治疗不同中医证型稳定型心绞痛的疗效观察

目的:探讨化痰通络颗粒治疗不同中医证型稳定型心绞痛(SAP)的疗效差异。方法:纳入219例瘀证SAP患者,并根据中医证型分为气虚血瘀组53例、痰瘀互结组63例、气滞血瘀组56例、痰浊闭阻组47例,另纳入50例瘀证SAP患者为对照组。所有患者均接受常规治疗,除对照组外,其余患者均在常规治疗基础上予化痰通络颗粒治疗,连续治疗4周。观察治疗前后中医证候疗效、心绞痛情况、心功能、脂代谢、凝血功能。结果:治疗后,气虚血瘀组、痰瘀互结组、气滞血瘀组、痰浊闭阻组患者疗效均优于对照组(P<0.05),且痰瘀互结组和痰浊闭阻组患者疗效均优于气虚血瘀组和气滞血瘀组(P<0.05)。治疗后,5组患者心绞痛症状积分均低于治疗前(P<0.05),且气虚血瘀组、痰瘀互结组、气滞血瘀组、痰浊闭阻组患者心绞痛症状积分均低于对照组(P<0.05),痰瘀互结组、痰浊闭阻组患者心绞痛症状积分均低于气虚血瘀组和气滞血瘀组(P<0.05)。治疗后,5组患者左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)均低于治疗前,射血分数(EF)、每搏输出量(SV)均高于治疗前(P<0.05),且痰瘀互结组、痰浊闭阻组患者LVEDD、LVESD均低于对照组,EF、SV均高于对照组(P<0.05)。治疗前痰浊闭阻组、痰瘀互结组患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)水平均高于气虚血瘀组、气滞血瘀组、对照组;治疗后,5组患者TC、TG、LDL均低于治疗前,HDL均高于治疗前(P<0.05)。治疗后,5组患者纤维蛋白原(FIB)、凝血酶时间(TT)均低于治疗前,活化部分凝血活酶时间(APTT)均高于治疗前,且痰瘀互结组、痰浊闭阻组患者FIB、TT水平均低于气虚血瘀组、气滞血瘀组和对照组(P<0.05)。结论:化痰通络颗粒治疗不同中医证型的稳定型心绞痛均有一定效果,联合西医治疗应用优于单独西医治疗,且其更适用于痰瘀互结证和痰浊闭阻证两种证型。

生脉散合千金苇茎汤加减治疗痰热壅肺型老年重症肺炎临床研究

目的:观察生脉散合千金苇茎汤加减治疗痰热壅肺型老年重症肺炎的临床疗效。方法:80例痰热壅肺型老年重症肺炎患者按随机数字表法分成对照组与观察组各40例。对照组给予常规西医对症治疗,观察组在对照组基础上给予生脉散合千金苇茎汤加减治疗,2组均连续治疗2周。比较2组治疗前后中医证候评分、临床肺部感染(CPIS)评分、多器官功能障碍综合征(MODS)评分、急性生理和慢性健康评分(APACHE Ⅱ)、肺功能指标[用力肺活量(FVC)、最大呼气流速峰值(PEF)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC]、白细胞计数(WBC)、降钙素原(PCT)、C-反应蛋白(CRP)、白细胞介素-6 (IL-6)水平;比较2组临床疗效及不良反应发生情况。结果:治疗后,观察组总有效率92.50%,高于对照组75.00%(P<0.05)。2组治疗后中医证候评分、CPIS评分、MODS评分、APACHE Ⅱ评分、WBC、PCT、CRP、IL-6水平均较治疗前降低(P<0.05),且观察组治疗后各项评分、炎症指标均低于对照组(P<0.05)。2组治疗后FVC、PEF、FEV_(1)水平及FEV_(1)/FVC均较治疗前升高(P<0.05),且观察组治疗后肺功能指标高于对照组(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:生脉散合千金苇茎汤加减治疗老年重症肺炎痰热壅肺证疗效确切,能够进一步缓解患者临床症状,抑制肺部炎症反应,改善肺功能,安全性较高。

姜桂二陈汤治疗慢性阻塞性肺疾病稳定期(寒痰阻肺型)的临床研究

目的 探讨姜桂二陈汤对慢性阻塞性肺疾病稳定期(寒痰阻肺型)患者的临床疗效。方法 选取2020年1月—2022年12月北京中医药大学房山医院肺病科诊治的慢性阻塞性肺疾病稳定期(寒痰阻肺型)患者100例,随机分为观察组和对照组。对照组患者给予以规范西医治疗,观察组在规范西医治疗同时加用姜桂二陈汤,比较两组患者临床疗效、中医症状评分、肺功能及BODE指数。结果 两组患者疗效相比观察组较优(P<0.05);治疗后,两组患者中医症状评分均明显降低,两组相比观察组较低(P<0.05);治疗后,两组患者6 min步行距离(6MWTD)较治疗前升高,且观察组高于对照组;治疗后,两组患者肺功能水平明显提高,两组相比观察组较高;BODE指数较治疗前降低,且观察组低于对照组(P<0.05)。结论 姜桂二陈汤治疗慢性阻塞性肺疾病(寒痰阻肺型),可提高患者临床疗效,缓解患者临床症状,可改善患者肺功能及肺气肿程度,增强患者运动耐量,从而改善患者预后。

通腑宣肺汤加味治疗儿童肺炎支原体肺炎痰热闭肺证临床研究

目的:观察通腑宣肺汤加味治疗儿童肺炎支原体肺炎痰热闭肺证的临床效果。方法:选择80例肺炎支原体肺炎痰热闭肺证患儿为研究对象,按随机数表法分为观察组和对照组各40例。2组均采用常规对症处理措施,对照组在常规治疗基础上采用阿奇霉素治疗,观察组在对照组基础上给予通腑宣肺汤加味治疗,2组均治疗7 d。评价2组临床疗效,比较2组症状改善时间,比较2组治疗前后中医证候积分、血清降钙素原(PCT)、C-反应蛋白(CRP)、白细胞介素-6 (IL-6)的水平,观察不良反应发生情况。结果:观察组总有效率为92.50%,高于对照组75.00%(P<0.05)。观察组咳嗽消失时间及肺啰音消失时间均短于对照组(P<0.05)。治疗后,2组主症、次症评分及中医证候总积分较治疗前降低(P<0.05),且观察组主症、次症积分及中医证候总积分均低于对照组(P<0.05)。治疗后,2组血清PCT、CRP、IL-6水平较治疗前降低(P<0.05),且观察组血清PCT、CRP、IL-6水平均低于对照组(P<0.05)。2组治疗期间均无严重不良反应发生。结论:通腑宣肺汤加味治疗儿童肺炎支原体肺炎痰热闭肺证的临床效果明显,能有效缓解症状,降低血清炎症因子水平,安全可靠。